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intravenous iron supplements. This treatment resulted in the
hematocrit rising to approximately 30% and the hemoglobin
concentration to 9.5 g/dL. The rest of the results (BUN, serum
creatinine, potassium, calcium, phosphorus) improved quickly
with the beginning of dialysis, and his blood pressure was well
controlled with enalapril (10 mg/day) and amlodipine (5 mg/
day). The dialysis sessions were uncomplicated and well toler-
ated; he had no cramps or episodes of hypotension. Concomi-
tant therapy included calcium carbonate (4 g/day) and oral
calcitriol (0.25 g/day). Tests of mineral metabolism (calcium,
phosphorus, and iPTH) were normal 4 years ago. The patient felt
relatively well, although he complained frequently of muscular
weakness, leg fatigue, and an inability to exercise vigorously.
He had given up his job and could not return to normal and
regular activity. He could walk only 5 blocks (10 minutes)
before having to stop because of leg fatigue.CASE PRESENTATION
Physical examination was normal. Blood tests, including se-
A 52-year-old white man with end-stage renal disease sec- rum sodium, potassium, magnesium, alanine aminotransferase
ondary to chronic nephroangiosclerosis began hemodialysis (ALT), glucose, calcium, phosphorus, intact parathyroid hor-
therapy 4 years ago. The patient has no family history of ar- mone (iPTH), cholesterol, triglycerides, muscle enzymes (cre-
terial hypertension and does not smoke. atine phosphokinase and aldolase), total protein, and albumin
The patient’s severe arterial hypertension and progressive were within the normal range; the hematocrit was 29% and
renal failure had been managed at the Renal Unit of Hospital hemoglobin 9.3 g/dL. Serologic tests for human immunodefi-
Clinic, University of Barcelona, for the past 16 years. His anti- ciency virus (HIV), hepatis C (HCV), and hepatitis B (HBV)
hypertensive treatment during this period consisted of a beta- virus were negative. Psychiatric evaluation revealed moderate
blocker (atenolol), a calcium-channel blocker (long-acting nifed- reactive depression, and treatment with fluoxetine hydrochlo-
ipine), and an angiotensin converting enzyme (ACE) inhibitor ride (Prozac) was started. Because the patient still complained
(enalapril). Unfortunately, his renal function declined progres- of weakness, the Epo dose was increased to 3500 IU subcutane-
sively and he required dialysis as of 4 years ago. An echocardio- ously after hemodialysis, and the intravenous iron supplement
gram showed moderate concentric left-ventricular hypertrophy was administered weekly.
with normal systolic function (fractional shortening of 65%). Over the next several weeks, the general well-being of the
The patient had been working as a car salesman for 10 years but patient improved, and he went back to regular work, 12 months
had to stop working 41⁄2 years ago because of weakness and de- after starting hemodialysis. He also tried to exercise regularly,
pression. He used to play tennis or swim two or three times per but he could not do so because he became weak and tired.
week, but after starting dialysis, he gave up all physical activity. The patient could not walk for distances longer than 500 meters
The patient’s initial hemodialysis prescription was 4 hours without calf pain because of tired legs. Three months after he
three times weekly; the prescription remains the same currently. had returned to work, an aorto-iliac digital subtraction angio-
Hemodialysis access was achieved by means of a Cimino-Brescia gram showed minimal signs of atheromatosis and no significant
arteriovenous fistula. Anemia was treated with erythropoietin stenotic lesions. Hematocrit was 38% and hemoglobin 12.5 g/dL;
(Epo), 2500 IU subcutaneously post hemodialysis, plus monthly the rest of the biochemical parameters were within the normal
range, including iPTH (120 ng/mL) and serum aluminum (5
g/mL). An electromyogram was within normal limits and did
Presentation of this Forum is made possible by grants from Amgen, not disclose any neuropathic or myopathic alterations. The
Incorporated; Merck & Company, Incorporated; Dialysis Clinic, Incor-
quality of the hemodialysis treatment was excellent, with aporated; and Bristol-Myers Squibb Company.
Kt/V of 1.5 and a C-reactive protein of 1.6. His physician
decided to prescribe carnitine (1 g intravenously post-hemodi-Key words: end-stage renal disease, hemodialysis, erythropoietin, exer-
cise tolerance, malnutrition, cardiomyopathy, carnitine deficiency, ex- alysis) because the patient still complained of severe muscular
ercise training. weakness and exercise limitation.
Three months later, the patient’s sense of well-being had 2002 by the International Society of Nephrology
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improved considerably. Although he still could not play tennis ation, with an overall prevalence of approximately 50%
or swim regularly and he experienced some weakness and fa- in dialysis patients [3].
tigue, he had returned to work, tolerated hemodialysis well, Several, often interrelated, risk factors for uremic my-
and could walk for 10 minutes at a moderate speed. opathy have been identified. Uremic myopathy is more
Two years ago, the patient received a renal transplant. The
frequent in female patients older than 60 years [4, 5].follow-up was successful, without acute rejection and with a
A significant correlation also exists between glomerulargood recovery of renal function (serum creatinine, 1.5 mg/dL).
filtration rate (GFR) and exercise tolerance or muscleThe patient’s physical activity improved and he restored his
peak oxygen uptake (peak VO2) [5, 6]. Uremic myopathyprevious sport activities, including swimming and tennis. He
did not complain of tiredness or fatigue. usually appears with a GFR under 25 mL/min and is rare
with a higher GFR. The progression of uremic myopathy
runs parallel to the decline in renal function, and the
DISCUSSION clinical manifestations of the entity become more appar-
Dr. Josep M. Campistol (Consultant Physician and ent when end-stage renal disease ensues. Although a close
Nephrologist, Renal Transplant Unit, Hospital Clinic, Uni- relationship exists between anemia and exercise limita-
versity of Barcelona, IDIBAPS, Barcelona, Spain): Uremic tion in uremic patients [7], the correction of anemia with
recombinant human erythropoietin (rHuEPO) or withmyopathy is a common alteration in patients with end-
blood transfusion does not completely restore musclestage renal disease, especially those undergoing dialysis
function in these patients [8]. I will discuss this lack of fulltherapy [1]. It manifests as muscular weakness, muscle
restoration of exercise capacity in detail in a few moments.wasting, limited endurance, exercise limitation, and easy
Certain systemic diseases, particularly diabetes andfatigability.
arterial hypertension, have been associated with uremicUremic myopathy was first described by Serratrice et
myopathy [9]. Hypertension and diabetes probably inter-al in 1967, who reported a group of patients with chronic
act through various mechanisms with the pathogeneticrenal failure and progressive proximal muscle weakness
factors of uremic myopathy, mainly a poor capillary net-caused by an intrinsic disorder of muscle function, pre-
work, thus intensifying the latter’s functional consequences.sumably secondary to uremia [2]. Despite extensive in-
The specific type of renal replacement therapy also ap-vestigation, many aspects of uremic myopathy, especially
pears to play a role. It has generally been shown thatits pathogenesis, remain unclear.
exercise tolerance in predialysis patients is greater thanSome confusion exists about the definition of uremic
that in hemodialysis patients, and it seems that there aremyopathy. Our group uses the term “uremic myopathy”
no significant differences between patients undergoingto refer to the constellation of functional and occasion-
peritoneal dialysis or hemodialysis [10]. Also, successfulally structural muscle abnormalities in patients with chronic
renal transplantation restores the exercise capacity ofrenal failure as a consequence of the uremic state itself.
uremic patients to near-normal limits, although theirIn general, physical examination, electromyographic stud-
peak VO2 remains lower than expected for normal indi-ies, and muscle enzymes are normal in dialysis patients
viduals of the same age and gender [11]. A sedentarydiagnosed with uremic myopathy; the relatively nonspe-
lifestyle is more frequently associated with uremic myop-
cific findings of fatigue, limited endurance, and exercise
athy and lower exercise tolerance [12]. Sedentary dialysis
limitation are the only clinical symptoms in most cases. patients have greater difficulty in restoring their exercise
Muscle biopsies occasionally reveal structural alterations, capacity than do non-sedentary patients after rHuEPO
mainly fiber atrophy, but the vast majority of patients therapy and/or successful renal transplantation [13]. This
are diagnosed clinically. For this reason, uremic myopa- association probably represents a vicious circle of events.
thy has various names, most of which refer to muscle Malnutrition, particularly amino acid deficiency, also has
functional abnormalities. In this Forum, we will consider been associated with uremic myopathy; muscle RNA con-
uremic myopathy predominantly a functional alteration tent rapidly falls during starvation in these patients [14].
of skeletal muscle in dialysis patients. Lastly, the presence of a severe cardiomyopathy with
left-ventricular hypertrophy has been related to the de-
Epidemiology and risk factors velopment of uremic myopathy, although the extent of
The epidemiology of uremic myopathy is not well de- this association remains uncertain [15]. The pathogenetic
fined. The literature contains no systematic studies on mechanisms involved in these abnormalities of myocar-
the prevalence of uremic myopathy in dialysis patients dium and skeletal muscle are probably similar and inter-
because (1) the clinical manifestations of uremic myopa- related, thus explaining their clinical association [16, 17].
thy are commonly minor and (2) no specific diagnostic
Pathogenesistool or biochemical parameter can definitively diagnose
uremic myopathy. Nonetheless, some reports have sug- The pathogenesis of uremic myopathy is incompletely
understood, despite the substantial information obtainedgested that uremic myopathy is a common clinical alter-
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with the introduction of physiologic studies and the use chondrial metabolism as the main factor responsible for
uremic myopathy and exercise limitation. Three groupsof 31P-magnetic resonance spectroscopy to evaluate mus-
cular bioenergetics. A central question is whether uremic of mitochondrial alterations have been considered: mito-
chondrial enzyme-oxidation alteration; excess lactic acidmyopathy is a functional abnormality of skeletal muscle
associated with uremia or an abnormality of muscle struc- production; and carnitine deficiency. Alteration in mito-
chondrial enzyme oxidation has been suggested as a mainture. To discuss this question, I have divided the patho-
genesis of uremic myopathy into three groups of factors: cause of exercise limitation in uremic patients [32]. Stud-
ies have shown a low concentration of aerobic enzymes(1) classic factors, in which uremic myopathy is consid-
ered more as an organic or structural abnormality and with an impairment of oxidative adenosine 5-triphos-
phate (ATP) synthesis in uremic muscle; therefore, thethe pathogenetic factors are directly related to the ure-
mic state; (2) muscle mitochondrial alterations, which rate of intracellular acidification is increased during exer-
cise because of increased dependence on anaerobic me-are directly related to abnormal function of muscle mito-
chondria; and (3) functional factors, in which uremic tabolism [33]. However, studies using 31P-spectroscopy to
determine cellular bioenergetics have demonstrated nor-myopathy is seen as more of a functional alteration of
skeletal muscle. mal indices of muscle metabolism in uremic patients,
apart from the presence of lower intracellular pH withAccording to a long-held view, the pathogenesis of ure-
mic myopathy has been related to many factors com- respect to controls [34]. Also, enzymatic studies in uremic
patients have shown normal ATP production [12, 35].monly associated with end-stage renal disease and dial-
ysis therapy. Uremic toxins (“middle molecules”), which We have investigated this aspect of uremic myopathy by
isolating muscle mitochondria from a group of dialysisare not effectively cleared by dialysis, accumulate and
are toxic to muscle [4, 18]. In 1969 Giovanetti et al claimed patients and performing several different functional stud-
ies [36]. We compared the results with those from athat injections of creatinine and methylguanidine pro-
duced severe muscle weakness in dogs [19]. A high per- control group of healthy sedentary subjects matched for
age and gender. Muscle mitochondria were isolated fromcentage of uremic patients, approximately 50%, have high
levels of ouabain, an endogenous digoxin-like factor that, muscle biopsies (vastus lateralis) using the method of
Rustin et al [37]. No significant differences in mitochon-when interacting with Na-K-ATPase, alters intracellular
calcium and other electrolytes, thereby impairing muscle drial oxidative activity between the dialysis patients and
the control group could be demonstrated. Neither wascontractility [20, 21]. Vitamin D metabolism abnormali-
ties are common in dialysis patients, and ionized calcium there any significant difference in the efficiency of oxida-
tive phosphorylation measured by the nanomoles ofplays an important role in the activation of myofibrillar
ATPase and in excitation-contraction coupling. A spe- adenosine diphosphate (ADP) phosphorylated to ATP
with glutamate, succinate, or ascorbate. We also checkedcific type of structural myopathy with fiber atrophy has
occasionally been described in patients with severe os- the specific activity of each individual complex of the
respiratory chain using spectrophotometric analysis andteomalacia [22]. Schott and Willis reported an improve-
ment in muscular weakness with the administration of found no differences between controls and dialysis pa-
tients in the enzymatic activities of complexes I throughcalcitriol [23]. Secondary hyperparathyroidism with oste-
itis fibrosa can be accompanied by a myopathy that closely V [36]. These results are in agreement with the data from
the bioenergetics studies that confirm the functional integ-resembles that seen in primary hyperparathyroidism [24].
Finally, severe aluminum intoxication has been associ- rity of muscle mitochondria in uremic patients.
Excess lactic acid production has been described inated with a proximal myopathy [25].
Insulin resistance, usually present in dialysis patients, uremic patients at submaximal exercise [39, 40]. In gen-
eral, the dialysis patients had 50% higher lactate produc-has been related to the development of uremic myopathy
because insulin resistance decreases the use of glucose tion and blood levels than did the normal controls for
the same-intensity exercise. The accumulation of intra-as an energy source [26]. Diabetic patients who undergo
dialysis have a higher prevalence and more severe forms cellular lactate in the exercising muscle causes a fall in
the intracellular pH that could interfere with normalof uremic myopathy [27]. There have been reports of
inhibited anaerobic glycolysis in uremic patients, both mitochondrial function by decreasing ATP production
[33, 40]. The rapid rise in blood lactate levels observed inin vivo and in vitro [4, 28, 29]. Malnutrition and wasting
appear to be common features in dialysis patients, espe- uremic patients with minimal exercise corroborated a
defect in mitochondrial glycolytic metabolism that re-cially in the elderly [30]. Malnutrition, especially with
protein deficiency, has been clearly associated with the sults in increased lactate production. We analyzed lactic
acid production and intracellular pH during maximaldevelopment of uremic myopathy, although many well-
fed dialysis patients have complained of muscular weak- exercise, comparing dialysis patients versus controls. In
agreement with previous workers, we demonstrated thatness and exercise limitation [31].
Several studies have focused on alterations in mito- lactic acid production was higher and intracellular pH
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was lower in exercising dialysis patients breathing a frac- limitation on the exercise performance of uremic patients
and later to assess the role of each of the two limitationtion of inspired oxygen (FiO2) of 0.21 [41]. On the other
hand, when oxygen availability was normal in dialysis factors I just mentioned. Eight sedentary, young, anemic
dialysis patients were enrolled in the first study, whichpatients (FiO2, 1.0), lactic acid production and intracellu-
lar pH were similar in the two groups [42]. These data used a cycle ergometer to determine exercise perfor-
mance in the uremic state and to evaluate the effects ofreflect a complete functional integrity of muscle mito-
chondria. rHuEPO therapy [41]. This study confirmed the exis-
tence of exercise limitation in uremia, with the dialysis pa-Carnitine deficiency has been related to the develop-
ment of uremic myopathy. A natural constituent of cells, tients reaching approximately 60% of the maximal work-
load of the control subjects. Treatment with rHuEPOcarnitine is located in the inner side of the mitochondrial
membrane and plays a fundamental role in skeletal mus- and normalization of the hemoglobin in uremic patients
were associated with only a slight increase in the maximalcle metabolism by promoting mitochondrial oxidation
of fatty acids [43]. Although studies have demonstrated workload. Erythropoietin therapy reversed the hyperdy-
namic state provoked by the anemia, thereby decreasingthat blood and muscle carnitine levels are low in dialysis
patients, some investigators have found normal levels of femoral venous blood flow and partially offsetting the
increase in oxygen delivery expected from the rise incarnitine in both blood and muscle [44, 45]. Lipid metab-
olism can be abnormal in dialysis patients even when car- arterial oxygen content. While rHuEPO enhanced aero-
bic capacity (approximately 30%), the relative increasenitine levels are in the normal range [43]. Controversy also
surrounds the effects of carnitine supplements adminis- was much less than that of the arterial oxygen content
(approximately 60%). This limited increase occurred de-tered to dialysis patients. Ahmad and colleagues, in a mul-
ticenter trial of dialysis patients in the United States, con- spite increases in the two major components of oxygen
transport from the atmosphere to the muscle cell aftercluded that l-carnitine improves exercise tolerance in
some patients, ameliorates the symptoms associated with rHuEPO—oxygen delivery and muscle oxygen conduc-
tance. Our data confirmed previous studies in which adialysis, and increases the overall sense of well-being;
these changes probably are related to an improvement disproportion between hemoglobin concentration and
exercise performance was observed in dialysis patientsin muscle function and protein metabolism [46].
The study of muscle functional alterations has been after rHuEPO therapy [47–49]. Collectively, our studies
[41] and previous studies [47–49] exclude anemia as therevolutionized by the introduction of techniques that per-
mit analysis of skeletal muscle during exercise. Application primary factor in the pathogenesis of uremic myopathy.
The next step in our research was to assess the limitingof the 31P-magnetic resonance spectroscopy (31P-MRS)
technique during exercising of skeletal muscle in vivo has factors for exercise performance in dialysis patients. To
confirm that mitochondrial oxidative capacity is normalprovided a noninvasive method for directly examining
intracellular energy metabolism. In 1993 Moore et al, in uremic patients and is not a limiting factor for muscle
maximal O2 uptake (peak VO2), we evaluated the oxy-using 31P-MRS examination, demonstrated subnormal
oxidative energy metabolism in the skeletal muscle of gen-supply dependence of maximal exercise and exam-
ined cellular bioenergetics using 31P-MRS. To examinedialysis patients but showed that the intrinsic ability to
generate ATP is not the cause of this abnormality [33]. whether oxygen-supply dependence of VO2 constrains
maximal exercise, it is necessary to perform studies ofThey proposed that this subnormal oxidative metabolism
is caused by limited exchange of metabolites, including maximal exercise with different FiO2 levels to determine
that the maximal oxygen utilization increases with O2oxygen, between blood and muscle, rather than by an
intrinsic oxidative defect in skeletal muscle. These data availability. Using three different values for FiO2 (0.13,
0.21, and 1.0), we demonstrated that dialysis patientsmodified the traditional view of uremic myopathy, until
then considered more a structural alteration than a func- indeed show oxygen-supply dependence of peak VO2;
this finding indicates a limitation on oxygen conductancetional abnormality. Moreover, physiologic studies on the
cardiorespiratory effects of recombinant human Epo between muscle capillary and mitochondria in uremic
patients (Fig. 1A). The cellular bioenergetics study using(rHuEPO) treatment in uremic patients suggest that the
increase in hemoglobin concentration suppresses the hy- 31P-MRS confirmed the data from Moore et al, namely,
that the metabolism of exercising muscle remains normalperdynamic cardiac state of uremic patients and modestly
improves aerobic exercise performance, disproportion- in uremic patients with no significant difference with re-
spect to the control group [35]. Further, we confirmedately to the increase in arterial oxygen content [47, 48].
Two functional factors need to be considered in the patho- that treatment with rHuEPO did not induce any change
in the cellular bioenergetics of uremic patients [50]. Thegenesis of uremic myopathy: anemia, commonly present
in dialysis patients, and existence of oxygen-supply depen- only abnormality observed with the 31P-MRS was a lower
intercellular pH (pHi) at any work rate during exercise indence of maximal exercise in skeletal muscle.
We undertook a series of studies first to confirm the uremic patients with respect to the control group (Fig. 1B).
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Fig. 1. (A) Relationship between leg quadriceps maximum O2 uptate
(peak VO2, L · min1) and work rate, expressed in grams, in uremic
patients and normal subjects breathing three different inspired O2 con-
centrations: hypoxia, normoxia, and hyperoxia. Patients with chronic
renal failure showed a strong linear relationship between peak VO2
and work rate, suggesting an oxygen supply dependency and indicating
a limitation on O2 transport from the capillary to the mitochondria.
Symbols are: () dialysis patients; () normal subjects. (Reprinted with
permission from J Clin Invest [41]). (B) 31P-MRS examination during
exercise, comparing cellular bioenergetics between uremic patients (;
breathing 100% O2) and the control group (; breathing 21% O2). No
significant differences could be demonstrated in cellular bioenergetics
between the two groups. (Reprinted with permission from J Clin Invest
[50]). (C ) Plot between the leg quadriceps peak O2 uptake (peak VO2
leg, L · min1) and oxymyoglobin saturation in uremic patients and
normal subjects breathing three different inspired O2 concentrations.
Oxymyoglobin saturation at a given FiO2 was lower in the uremic pa-
tients () than in the controls (). The lower the FiO2, the lower the
oxymyoglobin saturation within each group. The results obtained in
the two groups fit the same curve. (Reprinted with permission from
Am J Physiol [42].)
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Fig. 3. Northern blots for vascular endothelial growth factor (VEGF)
in skeletal muscle biopsies from uremic patients and control subjects
before (R) and after (E) exercise. VEGF-mRNA abundance is greatly
increased after exercise in both groups. Reprinted with permission from
Am J Physiol [38].
cle capillary O2 conductance is a major limiting factor of
peak VO2 in dialysis patients (Fig. 1C) [42]. Also, the
relationship between intracellular PO2 and peak VO2, as
FiO2 was varied, was identical in patients and controls.
This finding added to the evidence that mitochondrial
function is normal when O2 availability is normal.
Morphologic features
To investigate whether potential structural abnormali-
ties are responsible for reducing muscle oxygen conduc-
tance in dialysis patients, we performed two types of stud-
ies on muscle biopsy specimens (the vastus lateralis):
capillary assessment and angiogenic-growth-factor gene
response to acute exercise. No significant differences
could be demonstrated between uremic and control mus-
cles in several morphologic parameters, although thereFig. 2. (A) Muscle biopsy (vastus lateralis) of a patient with end-stage
renal failure on dialysis therapy. Transverse section stained simultane- was a trend toward a reduced capillary/fiber ratio in
ously with NADH tetrazolium reductase and Ulex europeus. Dark fibers uremic patients (1.33 vs. 1.43) (Fig. 2A). No differences
correspond to type-I fibers, pale fibers to type-II fibers, and black small
emerged in capillary density (274 vs. 260) because ofpoints between them are capillaries (magnification 100). (B) Electron
microscopy of a muscle biopsy from a dialysis patient. The capillary sur- reduction in fiber size (Table 1) [38]. Although not sig-
face, diameter, and capillary basement membrane were strictly normal, nificant, the percentage reduction in capillary number
with no significant differences from the control group (magnification
per fiber was similar to the reduction in functional O25000).
conductance; our findings substantiated prior work in
dogs [51]. Electron microscopy disclosed no differences
in the capillary diameter between the two groups, al-
We concluded that dialysis patients have a clear oxygen- though the thickness of the capillary basement membrane
supply dependency during maximal exercise, indicating was slightly wider in dialysis patients than in the control
an abnormal muscle oxygen conductance from muscle group (375 vs. 330, not significant) (Fig. 2B) [38]. Analy-
microcirculation to mitochondria, but functional integ- sis of angiogenic growth factor response focused on the
rity of muscle mitochondrial metabolism. These data were expression of vascular endothelial growth factor (VEGF-
reinforced by the application of proton MRS (1H-MRS), mRNA), transforming growth factor-1 (TGF-1) and
which allows the determination of myoglobin-O2 satura- basic fibroblast growth factor (bFGF) after acute exer-
tion and thus intracellular oxygen concentration [42]. cise (cycling for 60 min at submaximal workload). These
Our findings confirmed the oxygen-supply dependency results did not demonstrate any difference between dial-
of peak O2 uptake in dialysis patients. Further, the deter- ysis patients and the control group. The expression of
VEGF-mRNA was increased after exercise to the samemination of cellular PO2 suggested that reduced mus-
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Table 1. Morphologic capillary assessment in muscle in chronic
renal failure patients and controls
CRF patients Controls
Capillary assessment (N  5) (N  6) P value
Capillary density 274 (41) 260 (20) 0.48
Capillary/fiber ratio 1.33 (0.27) 1.43 (0.32) 0.59
Number of capillaries per fiber
Whole 3.44 (0.47) 3.88 (0.90) 0.35
Type I 3.70 (0.48) 4.11 (0.84) 0.36
Type II 3.16 (0.53) 3.67 (0.98) 0.33
Variability in capillaries per fiber
Whole 0.33 (0.07) 0.33 (0.05) 1.00
Type I 0.29 (0.10) 0.30 (0.03) 0.82
Type II 0.35 (0.06) 0.36 (0.08) 0.82Fig. 4. Densitometric data from the Northern blots, showing the large
increase in VEGF-mRNA with a single bout of exercise in uremic pa-
tients and control subjects. The increase was eightfold in dialysis patients
versus sixfold in the control group (P, not significant). Symbols are: ( )
rest; () exercise. Reprinted with permission from Am J Physiol [38].
We compared them with a control group of sedentary
healthy subjects of a similar age. We demonstrated no
significant differences between the dialysis patients andextent in both groups (Figs. 3 and 4) [38]. The normal
the control group in overall number of muscle fibers permorphology of the capillary network in uremic patients,
square millimeter, percentage of fibers type I and II,their normal angiogenic response to exercise, and our
fiber perimeter, variability index, cellular surface, andconviction that muscle oxygen conductance is reduced
histologic mitochondrial abnormalities (Table 2) [38].
in uremia (see earlier) suggest that a functional abnor-
Also, electronic microscopic examination did not dis-
mality is the main factor responsible for uremic myopa-
close any relevant differences between the two groups
thy and the associated limitation of peak oxygen uptake.
[38]. In conclusion, muscle morphology of dialysis pa-
Notwithstanding, we cannot exclude completely a reduc- tients generally is normal, although in underdialyzed pa-
tion in the ratio of capillaries per fiber and/or a wider tients and/or patients with marked secondary hyperpara-
capillary basement membrane in uremia. thyroidism, several muscle alterations can be identified,
Many muscle biopsy studies have described a variety mainly atrophy of the type-II fibers.
of morphologic changes in dialysis patients [13, 52–54].
Fiber atrophy probably represents the most common Clinical consequences
histologic finding in uremic myopathy, predominantly The two main clinical consequences associated with
involving type-II fibers, and particularly type IIb (fast uremic myopathy are exercise limitation and cardiomy-
fibers with anaerobic metabolism). Other significant opathy. Uremic myopathy usually is accompanied by weak-
changes observed are fiber splitting, internalized nuclei, ness, exercise limitation, limited endurance, and rapid-
nuclear knots, fiber degeneration and regeneration, fi- onset tiredness, although the degree of clinical expres-
bers without adjacent capillaries, increased content of sion of these manifestations varies widely [3]. In general,
lipid droplets, and altered distribution among the fiber physical examination, electromyogram, and muscle en-
types. Electron microscopic examination shows a variety zymes are normal. Various techniques have been used to
of changes consistent with mitochondrial damage and myo- evaluate exercise tolerance in dialysis patients, including
filament abnormalities (loss of myofilament and Z-band peak work capacity (PWC; highest workload performed
degeneration). in steady-state condition on a bicycle ergometer) or peak
Although all these histologic changes can be observed VO2. All the studies of PWC demonstrated values in di-
in muscle biopsies of some dialysis patients, there has alysis patients that averaged about 50% of those attained
been much criticism of the selection criteria for these pa- by control subjects matched for age and gender [3, 9].
tients and the type of muscle biopsied. We believe that In studies directly measuring peak VO2, values were only
biopsying the vastus lateralis is crucial because this mus- 60% of those expected for age-matched normals [41].
cle is the most representative for uremic myopathy. Pa- Proximal muscle weakness and rapid-onset tiredness,
tients biopsied in other studies do not represent the gen- common complaints in dialysis patients, are directly re-
eral pool of dialysis patients, and most of them presented lated to the presence of uremic myopathy. Generally,
with severe clinical manifestations of myopathy; in some patients with chronic renal failure have about 50% of
cases, they had advanced secondary hyperparathyroid- the muscle strength of their healthy counterparts [9].
ism. We recently performed a muscle biopsy (vastus lat- Leg fatigue has been the major reason for terminating
eralis) study on young sedentary dialysis patients who the exercise test in dialysis patients. In fact, Diesel et al
demonstrated a significant correlation between isoki-had no associated systemic disease (diabetes, vasculitis).
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Table 2. Muscle fiber composition in sedentary dialysis patients compared with age-matched sedentary healthy subjects
CRF patients Controls
Fiber type composition (N  5) (N  6) P value
Overall number of muscle fibers/mm2 210 (39) 190 (44) 0.45
TYPE I
Measured cellular surface lm2 4145 (922) 4345 (1555) 0.81
Corrected cellular surface lm2 2523 (300) 2502 (654) 0.95
Perimeter lm 266 (32) 274 (54) 0.79
Percentage respect to total fiber number 31 (6) 33 (8) 0.60
Percentage respect to total fiber surface 28 (5) 28 (9) 0.93
Variability index 0.33 (0.05) 0.28 (0.04) 0.09
TYPE II
Measured cellular surface lm2 4702 (903) 5708 (2355) 0.37
Corrected cellular surface lm2 2777 (282) 3299 (1130) 0.32
Perimeter lm 286 (38) 310 (75) 0.54
Percentage respect to total fiber number 69 (6) 67 (8) 0.60
Percentage respect to total fiber surface 72 (5) 72 (9) 0.93
Variability index 0.28 (0.06) 0.22 (0.05) 0.10
netic muscle strength and maximal aerobic capacity [55]. Management
Their findings suggested that impaired skeletal muscle We have no specific or effective treatment for uremic
function is a major factor influencing the decreased exer- myopathy. The best clinical approach is to prevent or
cise tolerance of uremic patients [55]. Several factors lower the risk factors of uremic myopathy and to improve
contribute to suboptimal cardiac function in patients with exercise tolerance in dialysis patients. Seven aspects need
chronic renal failure, particularly those undergoing main- to be considered in the management of uremic myopa-
tenance dialysis [56]. The myopathy that affects skeletal thy: (1) quality of the dialysis therapy; (2) prevention of
muscle presumably affects cardiac muscle as well. The secondary hyperparathyroidism; (3) nutritional status;
chronotropic cardiac response to exercise is limited; peak (4) carnitine supplementation; (5) correction of anemia
heart rate in a typical study was 77% of predicted and with rHuEPO; (6) exercise training programs; and (7)
was associated with reduced peak cardiac output [9]. renal transplantation.
Moreover, cardiovascular complications are the leading The literature contains no large prospective studies
cause of death in patients with end-stage renal disease. about the relation between the adequacy of the dialysis
Cardiac disease accounted for 40% of all deaths in dial- prescription (Kt/V) and the development of uremic my-
ysis patients in the United States and as many as 30% opathy. It is well known, however, that uremic myopathy
in Europe; ischemic heart disease was the most common is much more common in underdialyzed patients than in
cause [56]. Considerable evidence supports a higher prev- well-dialyzed patients. Not too surprisingly, a significant
alence, and possibly a more aggressive evolution, of coro- correlation has been demonstrated between a decrease
nary lesions in uremic patients, and a substantial pro- in GFR and the development of uremic myopathy [6].
portion of dialysis patients have ischemic heart disease The type of replacement therapy does not seem to be
without any evidence of significant coronary artery dis- associated with the development of uremic myopathy
ease [57]. Rostand et al determined that approximately and patient exercise tolerance [10]. No significant differ-
50% of patients with clinical signs of ischemic disease ences exist in the prevalence, incidence, and severity of
did not have any significant narrowing of coronary arter- uremic myopathy between patients on hemodialysis and
ies [58]. Such patients usually have severe left-ventricular those on peritoneal dialysis.
hypertrophy. In addition, cardiac tolerance to ischemia Secondary hyperparathyroidism has been clearly asso-
apparently is reduced in dialysis patients [59]. This ab- ciated with uremic myopathy [62]. Parathyroid hormone
normality can have both functional and structural causes, increases the entry of calcium into myocytes in a dose-
as Amman and colleagues demonstrated in experimental dependent manner by enhancing calcium influx through
animals [60] and in autopsy studies [61]. They showed the activation of the G protein voltage-dependent cal-
that the ratio of capillary-to-myofiber in the myocardium cium channel. The prevention and treatment of second-
is lower in dialysis patients and uremic animals than in ary hyperparathyroidism are essential elements in the
controls, including hypertensive patients. These abnor- management of uremic myopathy.
malities could induce an oxygen imbalance between sup- Anorexia and low nutritional intake, common mani-
ply and demand. This alteration has both functional and festations of uremia, have been associated with fatigue
and reduced exercise capacity in dialysis patients [14, 63].anatomic components.
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Defective muscle metabolism of amino acids represents crit for exercise tolerance and physical activity is around
one of the main factors for impaired muscle energy pro- 35% and never higher than 40% because of associated
duction in uremia [63]. Although few data are available adverse effects. Exercise and rHuEPO therapy are the
on the effect of protein and amino acid supplementation two most important elements in the management of ure-
on muscle protein synthesis and muscle function in dial- mic myopathy [9]. Moreover, erythropoietin stimulates
ysis patients, the correction of malnutrition is almost endothelial cells and thus is a potentially angiogenic fac-
always associated with improvement in the muscle amino tor [67] that could contribute to the restoration of capil-
acid pattern and exercise tolerance. A normal C-reactive lary supply in uremic muscles, including the heart.
protein (1.2) is a guarantee for the prevention of uremic Aerobic exercise training in healthy individuals facili-
myopathy. tates muscle oxygen utilization [68]. This change occurs
Carnitine deficiency traditionally has been related to as a result of increased concentration of oxidative en-
the development of uremic myopathy [43]. Clinical trials zymes and activity, increased proportion of type-I fibers,
of l-carnitine supplementation in uremic patients have increased capillary-to-fiber ratio, and increased total blood
produced conflicting results about its effects on lipid and flow. Well-performed studies give considerable insight
muscle metabolism, however. In general, after 6 to 12 into the potential benefits of exercise training in dialysis
months, l-carnitine supplementation slightly improved
patients [9, 69]. The magnitude of change ranges fromexercise capacity, muscle fiber atrophy, and muscle mass,
14% to 42% of exercise tolerance and/or peak VO2 in ure-although less than for matched controls [46, 64]. The
mic patients. The normal angiogenic gene response afterprevailing impression is that l-carnitine supplementation
acute exercise demonstrated in dialysis patients in partsubstantially improves exercise tolerance only in a sub-
might underlie this physiologic improvement [38]. In ad-group of dialysis patients [65]. The improvement of nutri-
dition to the increase in work tolerance, most of thetional status in some dialysis patients by the administra-
exercise training studies in dialysis patients have showntion of l-carnitine supplements is probably the key factor
other beneficial effects, such as improvement in bloodthat produces the beneficial effects of l-carnitine for
pressure control, reduction in serum triglycerides andmuscle function.
cholesterol, and improvement in glucose tolerance andRecombinant human erythropoietin, one of the last
overall quality of life [9, 70].decade’s most important advances in the management
As I said before, the combination of rHuEPO andof chronic renal failure, has been proven effective in
exercise training is essential to the management of ure-correcting the anemia of end-stage renal failure in more
mic myopathy. The increased feeling of well-being andthan 90% of patients [66]. The majority of clinical studies
have reported improvement in general quality of life, a reduced overall fatigue with rHuEPO therapy can render
feeling of well-being, and a slight increase in physical dialysis patients more willing to participate in exercise
activity following rHuEPO treatment [8, 47, 48]. The training programs. Patients also might be able to engage
effects of rHuEPO therapy on the cardiovascular system in a higher intensity of exercise than they could before,
are a reduction in the hyperdynamic state with a decrease and this change can result in greater gains in functional
in total cardiac output and muscle blood flow, and a capacity. Dialysis patients benefit from aerobic activities
subsequent increase in systemic vascular resistance (all such as walking, jogging, swimming, or stationary cycling.
explained by effects of higher hemoglobin concentration The intensity of exercise should be between 65% and 85%
on blood viscosity). As I said earlier, many studies have of maximal levels. The goal of 30 to 45 minutes of exercise
demonstrated only a small improvement in peak VO2 at target intensity per session should be attained, at a rate
after rHuEPO therapy despite increases in the hemoglo- of three sessions per week. Light exercise during hemodi-
bin concentration to almost normal levels. We and others alysis also has been demonstrated as beneficial [9].
demonstrated that treatment with rHuEPO was associ- Successful renal transplantation significantly increases
ated with an increase in hemoglobin concentration of peak VO2, although maximal exercise capacity remainsover 70%, although exercise tolerance and peak oxygen
at a level of about 80% to 90% of the expected normal foruptake did not change significantly (approximately 30%)
age-matched controls [10, 71, 72]. Thus, transplantation[8, 41, 50]. This small increase in exercise tolerance and
does not fully restore physical working capacity in renalmaximal oxygen uptake was achieved with a hematocrit
patients, especially in patients over age 60 [10, 71, 72].level around 35%; higher hemoglobin or hematocrit con-
The increase in exercise tolerance occurs within twocentrations do not improve further exercise tolerance.
months of renal transplantation and does not correlateWe also showed that cellular bioenergetics did not im-
with hematocrit [71]. When peak VO2 was repeated atprove after rHuEPO therapy [50]. However, the correc-
three months, there was no further increase above thetion of renal anemia with rHuEPO is essential for the
initial improvement [71]. Thus, the improvement in exer-management of dialysis patients and uremic myopathy.
cise tolerance after renal transplantation appears to beImprovement in quality of life is unquestionable, and
due to the correction of the uremic state, not to correc-the correction of anemia by rHuEPO will prove helpful
when physical activity is restarted. The optimal hemato- tion of anemia.
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QUESTIONS AND ANSWERS Dr. Campistol: The limitation in oxygen diffusion was
present in all dialysis patients we studied, and it wasDr. Nicolaos E. Madias (Executive Academic Dean,
independent of hematocrit. The presence of this limita-Tufts University School of Medicine, Boston, Massachu-
tion is only one of the diagnostic criteria for uremicsetts): Could you comment on muscle mass in uremia
myopathy in dialysis patients.and the magnitude of the increase in muscle blood flow
Dr. Madias: Let me expand on Dr. Valde´rrabano’sduring exercise in uremic patients as compared to normal
question. Are there dialysis patients who can sustain theindividuals?
same workload as non-uremic control subjects?Dr. Campistol: Muscle mass in uremic patients gener-
Dr. Campistol: No. The maximal workload of uremically is reduced essentially because of their sedentary
patients was lower than that in the control group, and thislifestyle. Muscle blood flow increases in dialysis patients
difference was statistically significant. Uremic patientsduring exercise 25% more than in the control group,
reached approximately 60% of maximal workload asbecause of the hyperkinetic status secondary to anemia.
matched controls.When we treated the patients with Epo and the hemoglo-
Dr. Alejandro Martin-Malo (Nephrology Depart-bin increased, muscle blood flow decreased significantly
ment, Hospital Universitario Reina Sophia, Cordoba,in parallel with the reduction in cardiac output [41, 50].
Spain): What is your opinion about the role of biocom-Dr. Madias: Of course, the uremic group you studied
patible membranes in uremic myopathy?was highly selected. How does the presence of hyperten-
Dr. Campistol: Biocompatibility likely plays a role insion or diabetes affect muscle blood flow during exercise?
uremic myopathy. I think that the quality of dialysis isDr. Campistol: It is true that the dialysis patients we
an important factor in uremic myopathy, and patientsstudied were selected. But this represents an important
with lower Kt/V have more severe forms of uremic my-point, because in this group of dialysis patients—young
opathy.adults without any systemic disease and who had been
Dr. Angel Argiles (ADSA-AIDER, Montpellier,on dialysis for only a short time—we could determine
France): You divided the pathogenetic factors into classi-
the presence of uremic myopathy in all, as defined by a
cal, mitochondrial, and functional. Would you reconcile
limitation in oxygen consumption. I explained during my the functional and ultrastructural changes you have re-
talk that other systemic diseases such as diabetes or hy- ported with the middle molecule theory? Could the in-
pertension might worsen the clinical parameters of ure- creased thickness in the capillary wall be a consequence
mic myopathy, because muscle blood flow will not in- of middle molecule retention?
crease as a consequence of anemia and limited oxygen Second, do you think that the new convective dialysis
diffusion. techniques could be useful in the treatment of uremic
Dr. Madias: Could you specify for us the characteris- myopathy? Should not only the use of high-flux mem-
tics of the uremic and the control groups? What were branes but also increased convection be sought?
the inclusion criteria for the uremic subjects? Were they Dr. Campistol: I agree with you that some middle
selected on the basis of manifesting clinical features of molecules could be essential by depositing on these mem-
uremic myopathy? Were the uremic subjects matched branes and making oxygen diffusion more difficult. This
for hypertension? concept is analogous to the deposition of glycosylated
Dr. Campistol: Dialysis patients and controls were sugar on the basement membrane of diabetic patients.
matched for age, gender, anthropometric characteristics, Further studies need to focus on this topic.
lifestyle, and smoking habits. The presence of hyperten- Regarding your second question, yes, I agree. The best
sion, diabetes, or any other systemic disease (such as vas- way to prevent the development of uremic myopathy is
culitis) were reasons for exclusion. None of the selected to give the best-quality dialysis therapy. With the use of
dialysis patients presented any specific clinical manifesta- high-flux membranes, we can attain the best quality of
tions of uremic myopathy. In point of fact, the presence hemodialysis.
of any clinical feature of uremic myopathy was reason Dr. Pablo In˜igo (Renal Transplant Unit, Hospital
for exclusion. Clinic, Barcelona, Spain): You have shown that the abun-
Dr. Fernando Valde´rrabano (Chief of Nephrology, dance of VEGF mRNA in muscle biopsies from dialysis
Hospital Universitario, Gregorio Maran˜on, Madrid, Spain): patients after acute exercise was normal, although you
It is difficult to know the frequency of uremic myopathy demonstrated a slight decrease in the number of muscle
in ESRD patients, because there are no clear diagnostic capillaries. How do you explain this discrepancy?
criteria. Are the limitation in oxygen diffusion capacity Dr. Campistol: Although we have demonstrated that
and the disproportion between the increase in hemato- the abundance of VEGF mRNA was normal after acute
crit and peak VO2 that you found in your studies present exercise in dialysis patients, the angiogenic process is
in all uremic patients, or only in uremic patients with complex, and we studied only a small part of this process.
Deficiencies other than VEGF production (mRNA) couldmyopathy?
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explain the trend toward a reduced capillary/myofiber to erythropoietin therapy. The use of carnitine is wide-
spread in the US but very limited in Europe. I recom-ratio observed in dialysis patients.
Dr. Madias: You indicated that following treatment mend carnitine when a patient has symptoms of severe
uremic myopathy.with erythropoietin, maximal O2 uptake increases as a
consequence of increased O2 delivery. Isn’t it possible Dr. Jordi Pascual (Nephrology Department, Clinica
Girona, Girona, Spain): Are there changes in hemoglo-that this beneficial effect of rHuEpo also includes better
conditioning of the patient as a result of an improved bin or blood viscosity in patients treated with carnitine?
Dr. Campistol: No, there are no significant changessense of well-being?
Dr. Campistol: Yes, part of this improvement could in hematocrit or hemoglobin during carnitine therapy,
although, as I said, it does seem that the response tobe related to improvement in the sense of well-being, as
is true in the general population. erythropoietin therapy is better.
Dr. Pascual: Did you study all the mitochondrial en-Dr. Maria Teresa Gonzalez-Alvarez (Hospital de
Bellvitge, Barcelona): Angiotensin-converting-enzyme in- zyme complexes in dialysis patients?
Dr. Campistol: Yes, we studied five mitochondrialhibitors reduce the response to Epo therapy. Do you think
that these drugs contribute to the development of uremic complexes in dialysis patients and in a control group,
and we could not demonstrate any significant differences.myopathy?
Dr. Campistol: Although ACE inhibitors have been Dr. Jose´ Carlos Rodriguez-Perez (Nephrology De-
partment, Hospital de Gran Canaria, Las Palmas de Granrelated to the development of anemia and erythropoietin
resistance, I don’t think that they have any role in the Canaria, Spain): Do you know of any studies on the role
of the NO pathway in uremic myopathy?development of uremic myopathy. With respect to other
antihypertensive drugs, beta-blockers have been related Dr. Campistol: No, I am not aware of such studies.
An imbalance in this pathway has been demonstratedto uremic myopathy, as they decrease muscle blood flow.
Dr. Madias: What is the consequence of endurance in hypertensive dialysis patients, and this could explain
the functional mismatch of capillaries and myofibers ob-training in dialysis patients? Does it affect lactate genera-
tion and muscle bioenergetics? served in these patients.
Dr. Aleix Cases (Nephrology Department, HospitalDr. Campistol: Several studies clearly show that en-
durance training in dialysis patients slightly improves Clinic, Barcelona): Patients on CAPD do better than
patients on hemodialysis with respect to uremic myopa-exercise tolerance and peak VO2. The reasons for this re-
sponse are not completely clear. The only data that we thy. What might be the reason for this difference?
Dr. Campistol: There is some confusion in the litera-have in dialysis patients is a normal angiogenic gene
response after acute exercise [38]. We don’t have data ture about this topic, although most of the groups found
no significant differences between patients on hemo- oron lactate production, although an increase in oxidative
enzymes might produce a decrease in lactate production. peritoneal dialysis [10, 73, 74]. Painter et al showed simi-
lar peak VO2 between patients on peritoneal dialysis andDr. Jose´ Vicente Torregrosa (Renal Transplant Unit,
Hospital Clinic, Barcelona): You mentioned that calcitriol hemodialysis, although they demonstrated better heart
rate in peritoneal dialysis patients [10]. The exact reasoncould improve uremic myopathy. Does calcitriol have a
direct or an indirect effect on muscle? for this is not clear, but causative factors could include a
better clearance of middle molecules with CAPD. OtherDr. Campistol: Calcitriol could have a beneficial effect
on uremic myopathy by controlling secondary hyper- factors, such as higher hematocrit or better hemody-
namic stability, also have been proposed. Schmidt et alparathyroidism. There is clear evidence of a specific type
of myopathy associated with osteomalacia or vitamin D demonstrated a low production of nitric oxide in perito-
neal dialysis patients [74].deficiency and accompanying secondary hyperparathy-
roidism. Treatment with calcitriol allows good control Dr. Luis Orte (Nephrology Department, Hospital Ra-
mo´n y Cajal, Madrid): Do you have any knowledge ofof secondary hyperparathyroidism and prevention or
amelioration of the associated myopathy. possible biochemical markers of uremic myopathy like
plasma levels of homocysteine, fibrinogen, factor VIII,Dr. Manolo Arias (Chief, Nephrology Department,
Hospital Valdecilla, Santander, Spain): The use of carni- etc.?
Dr. Campistol: Unfortunately, there are no biochemi-tine appears quite different in Europe than in the United
States. Could you summarize the clinical criteria for car- cal markers of uremic myopathy. All the studies in this
area have been frustrating, and no positive results havenitine prescription in hemodialysis patients?
Dr. Campistol: There is no clear evidence demonstra- been obtained to date.
Dr. Alberto Tejedor (Nephrology Department, Hos-ting that treatment with carnitine improves muscle me-
tabolism and function, although several papers have pital Universitario, Gregorio Maran˜on): In 1988, Vinay
and Cardoso pointed out the relevance of acetate/bicar-demonstrated that treatment with carnitine is associated
with a sense of well-being and probably a better response bonate dialysate in uremic muscle function [75]. Do you
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poietin on exercise capacity in hemodialysis patients. Adv Ren Re-have any information about myokinase activity in dialysis
place Ther 1:55–65, 1994
patients with uremic myopathy? Do you think the substi- 9. Casaburi R: Rehabilitation exercise training in chronic renal fail-
ure, in Nutritional Management of Renal Diseases, edited by Koppletution of bicarbonate for acetate in the dialysate has
JD, Massry SG, Baltimore, Williams & Wilkins, 1997, pp 817–842improved the muscle function of dialysis patients and
10. Painter P, Rehak-Messer D, Hanson P, et al: Exercise capacity
decreased the prevalence of uremic myopathy? in hemodialysis, CAPD, and renal transplant recipients. Nephron
42:47–51, 1986Dr. Campistol: I don’t have any data on myokinase
11. Kempeneers G, Noakes TD, Zyl-Smit R, et al: Skeletal muscleactivity in dialysis patients with uremic myopathy. I sus-
limits the exercise tolerance of renal transplant patients: Effects
pect that the correction of metabolic acidosis with bicar- of a graded exercise training program. Am J Kidney Dis 16:57–
65, 1990bonate rather than acetate in the dialysate is better for
12. Thompson CH, Kemp GJ, Barnes PRJ, et al: Uraemic musclemuscle function, although I don’t know of a study com- metabolism at rest and during exercise. Nephrol Dial Transplant
paring muscle function in patients dialyzed with bicar- 9:1600–1605, 1994
13. Kouidi E, Albani M, Natsis K, et al: The effects of exercisebonate and those dialyzed with acetate. The important
training on muscle atrophy in hemodialysis patients. Nephrol Dialpoint is to correct acidosis as far as possible. Transplant 13:685–699, 1998
Dr. Madias: Increasing evidence suggests that several 14. Guarnieri G, Toigo G, Situlin R, et al: Muscle biopsy studies in
chronically uremic patients: Evidence for malnutrition. Kidney Intill effects of the ESRD state have their origin in the pre-
24(Suppl 16):187–193, 1983
ESRD period. What advice would you give to nephrolo- 15. Raine AE, Seymour AM, Roberts AF, et al: Impairment of cardiac
function and energetics in experimental renal failure. J Clin Investgists about the management of pre-dialysis patients as it
92:2934–2940, 1993relates to the development of uremic myopathy?
16. Amann K, Neususs R, Ritz E, et al: Changes of vascular architec-
Dr. Campistol: Control of secondary hyperparathy- ture independent of blood pressure in experimental uremia. Am
J Hypertens 9:409–417, 1995roidism, correction of anemia using rHuEpo, and ade-
17. London GM, Fabiani F, Marchais SJ, et al: Uremic cardiomyopa-quate nutrition are essential in the pre-dialysis period.
thy: An inadequate left ventricular hypertrophy. Kidney Int 31:973–
980, 1987
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